Teladoc Q2 revenue down 2% but beats expectations
Overview
Teladoc Q2 revenue falls 2% to $631.9 mln, but beats analysts' expectations, per LSEG data
Adjusted EBITDA down 23% to $69.3 mln, also beating expectations
Co retired $550.6 mln in convertible notes, secured $300 mln credit facility
Outlook
Teladoc expects full-year 2025 revenue of $2.501 bln to $2.548 bln
Company projects full-year adjusted EBITDA of $263 mln to $294 mln
Teladoc anticipates Q3 2025 revenue between $614 mln and $636 mln
Company forecasts Q3 2025 adjusted EBITDA of $56 mln to $70 mln
Result Drivers
INTEGRATED CARE GROWTH - Integrated Care segment revenue increased 4% year-over-year, driven by disciplined execution and strategic investments
BETTERHELP DECLINE - BetterHelp segment revenue fell 9% year-over-year, reflecting challenges in the direct-to-consumer market
CREDIT FACILITY - Co secured a $300 mln credit facility to enhance financial flexibility, per CEO Chuck Divita
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $631.90 mln | $622.70 mln (23 Analysts) |
Q2 EPS | -$0.19 | ||
Q2 Net Income | -$32.66 mln | ||
Q2 Adjusted EBITDA | Beat | $69.31 mln | $63.50 mln (22 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 22 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Teladoc Health Inc is $8.38, about 2.1% above its July 28 closing price of $8.20
Press Release:
